|

Lymph Node Pathologic Grading Strategy

RECRUITINGSponsored by Fudan University
Actively Recruiting
SponsorFudan University
Started2024-04-10
Est. completion2024-12-30
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06745830

Summary

The percentage of high-grade patterns in metastatic LNs (mLNs) that can predict poor outcomes has yet to be determined. Additionally, the potential implications of other histologic patterns in metastatic lymph nodes on patient outcomes warrant further investigation. We conducted a retrospective cohort study to investigate the prognostic value of pathologic pattern in metastatic lymph nodes.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

From January 2011 to September 2021, we consecutively collected patients with invasive LUAD who underwent surgical resection at the Department of Thoracic Surgery, Fudan University Shanghai Cancer Center.

Exclusion Criteria:

1. adenocarcinoma in situ, minimally invasive adenocarcinoma, invasive mucinous adenocarcinoma, and other variants of adenocarcinoma;
2. incomplete common driver mutation data;
3. unavailable pathologic slides.

Conditions3

CancerLung AdenocarcinomaLung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.